Contact
Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104
TO:
Please use this form to send email to PR contact of this press release:
OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104
TO: